Dr. G's Weightloss

Dr. G's Weightloss in Doral, Florida operates under the medical direction of Richard Kowalsky, MD, FACOG, a board-certified physician with certification from the American Board of Obesity Medicine. The clinic structures its weight management programs around physician-supervised protocols that integrate GLP-1 receptor agonists—specifically Semaglutide and Tirzepatide—alongside growth hormone-releasing peptides like Sermorelin for patients whose metabolic profiles indicate hormone optimization as part of their treatment plan. Dr. Kowalsky's dual background in obstetrics and gynecology combined with obesity medicine certification positions the practice to address weight concerns that intersect with hormonal transitions, metabolic dysfunction, and age-related changes in body composition.

The clinic's peptide therapy protocols center on three primary agents, each selected based on patient-specific metabolic assessments and weight loss objectives. Semaglutide and Tirzepatide function as incretin mimetics that regulate appetite, slow gastric emptying, and improve glycemic control, making them appropriate for patients with insulin resistance or type 2 diabetes alongside obesity. Sermorelin, a growth hormone secretagogue, is incorporated into treatment plans when evaluation reveals diminished growth hormone production contributing to increased adiposity, reduced lean muscle mass, or impaired recovery from exercise. Treatment plans in Doral are individualized following comprehensive metabolic panels, body composition analysis, and review of prior weight loss attempts, with dosing adjusted based on patient response and tolerance rather than following a single protocol for all patients.

Dr. Kowalsky conducts initial consultations in person at the Doral clinic location, where patients undergo baseline assessments including metabolic rate testing, hormone panels, and nutritional evaluation before peptide therapy initiation. The practice employs nursing staff who manage follow-up visits, monitor patient progress through regular weigh-ins and symptom tracking, and adjust medication dosing under physician oversight. Nutritionist consultations are integrated into the program structure, providing patients with meal planning guidance that complements the appetite-regulating effects of GLP-1 medications and supports the anabolic benefits of Sermorelin when prescribed. This collaborative model allows for frequent touchpoints without requiring physician visits for every adjustment, while maintaining medical supervision throughout the treatment course.

Patients beginning treatment at Dr. G's Weightloss in Doral can expect an initial consultation that includes medical history review, physical examination, laboratory work, and discussion of realistic weight loss timelines based on their starting metabolic parameters. Semaglutide and Tirzepatide are typically initiated at low doses with gradual titration over 16-20 weeks to minimize gastrointestinal side effects while achieving therapeutic appetite suppression. Sermorelin, when indicated, is administered via subcutaneous injection in the evening to align with natural growth hormone pulsatility, with patients taught self-injection technique during their first nursing visit. The practice schedules follow-up appointments every two to four weeks during the initial treatment phase, with nursing staff available between visits to address questions about injection technique, side effect management, or nutritional concerns that arise as eating patterns change.

The clinic's location in Doral, Florida serves patients throughout Miami-Dade County seeking medical weight loss programs that extend beyond dietary counseling alone. Dr. Kowalsky's certification in obesity medicine reflects specialized training in the pathophysiology of weight regulation, pharmacotherapy for obesity, and the medical complications associated with excess adiposity—knowledge that informs peptide selection and monitoring protocols. The practice requires in-person visits for treatment initiation and key monitoring points, ensuring that patients receive hands-on assessment of treatment response, side effect evaluation, and program adjustments based on objective measures rather than remote reporting alone. This structure supports accountability while providing the medical oversight necessary for safe peptide therapy administration in a weight loss context.